Chairman Shi Yuanyuan Visits Guangzhou Fuli Hospital to Explore New Developments in the Cell Therapy Industry

On August 15, Shi Yuanyuan, Chairman of Shenzhen Cell Valley, and R&D Scientist Yang Yiqing visited Guangzhou Fuli Hospital and engaged in in-depth discussions with Director Chen Tao, Head of Immunotherapy at the Hospital's Center of Excellence for Oncology, and his team, focusing on the innovative development and application prospects of immune cell therapy.

During the exchange meeting, Director Chen Tao first introduced the construction and treatment philosophy of Guangzhou Fuli Hospital, noting that the hospital is an international general hospital operating in compliance with dual accreditation standards of "International Medical Standards" and "International Medical Information Management Standards." The two sides discussed the latest research findings, technological advancements, and market trends in the field of immune cell therapy, aiming to identify cooperation opportunities and jointly promote the emerging development of the cell therapy industry. Professor Shi Yuanyuan pointed out that Shenzhen Cell Valley's core R&D team has successfully utilized self-produced industrial-grade retroviral vectors to prepare CAR-T cell products targeting over 50 targets. With high transduction efficiency and stringent release standards, these products have demonstrated excellent safety and efficacy in clinical research at multiple domestic medical institutions, truly embodying the vision of "Cells benefit all."

Director Chen Tao expressed appreciation for Shenzhen Cell Valley's core technologies and corporate vision, noting that he had previously visited Shenzhen Cell Valley's headquarters in Shenzhen. The purpose of this invitation was to facilitate a site visit to the hospital and achieve deeper cooperation in the field of immune cell therapy with Cell Valley.

Through this visit, both parties expressed the hope to establish a long-term, comprehensive cooperative relationship, jointly address industry challenges, promote the widespread application of immune cell therapy technologies, and bring more treatment options and hope to patients.

About Guangzhou Fuli Hospital

Guangzhou Fuli Hospital is a high-end non-public international general hospital with an investment exceeding RMB 3 billion. It was designed and constructed with full participation from UCLA Health, a top international medical institution, and is equipped with world-class first-line cutting-edge medical facilities and equipment. The hospital has assembled a team of top-tier experts from large domestic tertiary hospitals and internationally renowned institutions, including recipients of the State Council Special Allowance. The oncology department is staffed by a professional team of distinguished experts and nursing personnel from major oncology centers and specialty cancer hospitals. The department focuses on chemotherapy, targeted therapy, and immunotherapy to provide comprehensive treatment. With high-end diagnostic and therapeutic technologies and a multidisciplinary collaborative treatment model, the hospital develops the most advanced, individualized, and humanized high-quality precision treatment plans for each cancer patient, complemented by warm and comfortable nursing services. It provides full-process services ranging from cancer health education, diagnosis, and treatment to rehabilitation and mental health counseling.